A Phase IIb, Randomized, Double-blind, Multicenter Study Evaluating the Efficacy of Botulinum Toxin Versus Placebo on Pain and Health Related Quality of Life of Patients With Piriformis Muscle Syndrome

Piriformis muscle syndrome (PMS) is characterized by symptoms caused by compression or irritation of the sciatic nerve by the piriformis muscle as it exits the sciatic notch. PMS commonly evokes the symptoms of sciatica and is likely underdisagnosed. Patients who experience pain related to piriformis syndrome will complain of aggravated pain after prolonged periods of sitting or upon rising from a seated position. Around 98% of patients evoke positional buttock pain, especially during prolonged sitting (car journeys, for example). This is less true for sciatic pain radiation, which is still found in 63% of cases, systematically associated with the notion of buttock pain. Treatments for PMS aim to reduce or eliminate sciatic pain and also control buttock pain. Reducing these pains can improve the physical condition and emotional state of the patient. Several approaches have been proposed including physical therapy (massage-physiotherapy, self-rehabilitation techniques) combined with the use of anti-inflammatory drugs, analgesics and muscle relaxants to reduce inflammation, spasm and pain. Many patients do not respond to conventional care. Surgery may be considered only in those cases who do not improve with conservative therapy or injections. However, decompressive surgery is an invasive treatment, indicated in case of complete failure of all medical strategies, with physical and functional consequences. In recent years, several published studies showed the use of botulinum toxin (BT) injection as a new therapeutic option to reduce buttock and sciatic pain induced by PMS. The study team previously observed the efficacy of BT/A1 administration into the piriformis muscle in patients who were previously treated with medication and rehabilitation protocols with no pain improvement. Pain relief was considered as "very good" or "good" for 77% of the patients, "average" for 7.4% and "poor" for 15.6%. No adverse events were reported. More recently, Fishman and colleagues reported the results of a randomized, double-blind, controlled study including 56 patients and comparing physical therapy, incobotulinum toxin A and placebo. Data are sparse concerning BT injection for PMS and no multicenter randomized clinical trial have been performed. Two out of three randomized trials (Fishman 2004, 2017) are based on highly selected patients (3 standard deviations or more beyond on the prolongation of the posterior tibial or fibular nerve H-reflex in FAIR test). Therefore, BT efficacy may be overestimated and remains to be evaluated among unselected PMS patients, regardless of analgesic treatments or physical therapy. Finally, no randomized studies have reported the heatlh-related quality of life of PMS patients.

开始日期2026-07-01

申办/合作机构

Centre Hospitalier Universitaire de Nimes

NCT07537855

/ Not yet recruiting临床2期IIT

Clinical Efficacy of Intracavernosal Xeomin as an Adjunctive Therapy to on Demand Tadalafil 20 mg for the Treatment of Mild to Moderate Erectile Dysfunction: A Randomized Crossover Pilot Study

Erectile dysfunction (ED) affects approximately 30 million men in the United States and is associated with factors such as aging, smoking, diabetes, hypertension, obesity, and sedentary lifestyle. ED can also negatively impact the quality of life of patients and their partners. Treatment decisions are typically made jointly between patients and their urologists, often starting with less invasive options. Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors), including sildenafil, tadalafil, and vardenafil, are commonly used as first-line therapy. While these medications improve erectile function in many patients, approximately 30-40% do not respond adequately to PDE5 inhibitor therapy alone. Patients who do not achieve sufficient benefit may require additional or more invasive treatment options.

开始日期2026-06-01

申办/合作机构

Northwestern University

[+1]

JPRN-jRCT2031260082

/ RecruitingN/A

Xeomin 50 units, 100 units, 200 units for injection Special Drug Use-Results Survey (Chronic Sialorrhea)

开始日期2026-04-23

申办/合作机构

Teijin Pharma Ltd.

100 项与 A型肉毒毒素 (Biotecon) 相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素 (Biotecon) 相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素 (Biotecon) 相关的专利（医药）

登录后查看更多信息

459

项与 A型肉毒毒素 (Biotecon) 相关的文献（医药）

2026-06-01·UROLOGY

IncobotulinumtoxinA Versus OnabotulinumtoxinA for Treatment of Overactive Bladder Syndrome: A Randomized Single-blinded Non-inferiority Trial

Article

作者: Gisseman, Jordan D ; Olsen, Cara ; Hamade, Sara J ; Vaccaro, Christine M ; Trikhacheva, Anna S ; Dengler, Katherine L

OBJECTIVE:

To compare the efficacy of incobotulinumtoxinA to onabotulinumtoxinA for the treatment of idiopathic overactive bladder syndrome.

METHODS:

This study is a single-blinded, randomized, non-inferiority trial. Participants received intradetrusor injections of either 100 units of incobotulinumtoxinA or 100 units of onabotulinumtoxinA. The primary outcome was measured as a change in the mean number of urgency urinary incontinence episodes from baseline to 2-6 weeks post-procedure.

RESULTS:

Data from 59 participants were analyzed (29 incobotulinumtoxinA, 30 onabotulinumtoxinA). Most participants were between 40 and 59 years of age and postmenopausal. There were significantly more postmenopausal participants in the onabotulinumtoxinA group (51.72% incobotulinumtoxinA, 80% onabotulinumtoxinA, P<.05). Comparing incobotulinumtoxinA to onabotulinumtoxinA, the difference in mean reduction of urgency urinary incontinence episodes from baseline to 2-6 weeks post-treatment was 0.41 (90% confidence interval -0.88 to 1.71), meeting the predetermined non-inferiority margin of -1. The mean daytime voids decreased by 0.97 ± 2.54 from baseline of 7.28 ± 2.77 in the incobotulinumtoxinA group, and by 2.97 ± 4.74 from baseline of 9.57 ± 5.61 in the onabotulinumtoxinA group (P<.05). The Patient Global Impression of Improvement scores were significantly different between the 2 groups (2.57 ± 1.34 IncobotulinumtoxinA, 1.93 ± 0.83 OnabotulinumtoxinA [P<.05]). However, the number of participants answering "very much better" and "much better" was similar between the groups (64% IncobotulinumtoxinA, 71% OnabotulinumtoxinA). There was no statistically significant difference in other secondary outcomes or with adverse events between the 2 groups.

CONCLUSION:

Intradetrusor incobotulinumtoxinA was found to be non-inferior to onabotulinumtoxinA in the treatment of idiopathic overactive bladder syndrome and offers a more pure, cost-effective, and logistically convenient alternative.

2026-06-01·ADVANCES IN THERAPY

Real-World Switch Rates, Treatment Patterns, and Healthcare Costs Among Patients With Spasticity Treated With Botulinum Toxins

Article

作者: Shah, Darshini ; Manthena, Shivaji ; Dominguez, Annaliza ; Cheng, Ning

INTRODUCTION:

Botulinum toxin type A therapies are FDA-approved for the treatment of adult spasticity and recognized as standard of care; however, comparative real-world data on treatment patterns and costs are limited. This study aimed to compare switch rates, healthcare resource utilization (HCRU), and costs among patients with spasticity initiating onabotulinumtoxinA, abobotulinumtoxinA, or incobotulinumtoxinA.

METHODS:

Adult patients with spasticity receiving botulinum toxins between January 1, 2017, and December 31, 2023, were identified from Optum's de-identified Clinformatics^® Data Mart Database. Patients must have had ≥ 12 months of continuous enrollment before and after toxin initiation. Outcomes included switch rates and all-cause, spasticity-related, fall-related, fracture-related, and toxin-related healthcare resource utilization and costs.

RESULTS:

Among 1714 eligible patients, 1521 initiated onabotulinumtoxinA (88.7%), 99 initiated abobotulinumtoxinA (5.8%), and 94 initiated incobotulinumtoxinA (5.5%) as index treatment. Switch rates at 12 months post-index were lowest for onabotulinumtoxinA (1.4%) compared with abobotulinumtoxinA (4.0%), and incobotulinumtoxinA (10.6%). OnabotutlinumtoxinA initiators demonstrated lower total all-cause medical costs and fracture-related costs compared with incobotulinumtoxinA and abobotulinumtoxinA, respectively, with comparable healthcare resource utilization and other costs.

CONCLUSION:

Most patients initiated onabotulinumtoxinA with lower switch rates than those who initiated with incobotulinumtoxinA and abobotulinumtoxinA. Total costs were comparable between treatments, except for all-cause medical costs and fracture-related costs, which were lower among onabotulinumtoxinA initiators.

2026-05-14·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Endoscopic diagnosis of neurogenic dysphagia and quantitative visual scale assessment of posterior sialorrhea for the prevention of aspiration events in adults

Article

作者: Pogoreltseva, O.A. ; Belkin, A.A. ; Agafonov, S.S. ; Khatkova, S.E. ; Baturova, V.Yu.

Objective. This study aimed to evaluate the efficacy and safety of intrasalivary injections of incobotulinumtoxinA for the prevention of aspiration complications in patients with neurogenic dysphagia and posterior sialorrhea of various etiologies. Material and methods. This prospective study, conducted from 2024 to 2025, included 116 patients divided into two groups. The Main group (n=58) received ultrasound-guided chemodenervation of four salivary glands (two parotid and two submandibular) with incobotulinumtoxinA at a total dose of 100 U. The Control group (n=58) comprised retrospective data from patients with similar clinical profiles who did not receive botulinum toxin injections. All participants underwent a comprehensive diagnostic evaluation, including neurological assessment, instrumental methods such as a videofluoroscopic swallow study (VFSS) and a chest computed tomography (CT) scan, and non-instrumental scales for dysphagia and cognitive function. To quantify the severity of posterior sialorrhea, a Posterior Sialorrhea Intensity Visual Scale (PSIVS) ranging from 0 to 3 points was developed and applied. Efficacy was evaluated based on changes in sialorrhea intensity, feeding route, aspiration pneumonia incidence, and timing of tracheostomy decannulation. Results. By day 28 post-injection, the majority of patients in the Main group (54 out of 58) demonstrated a significant reduction in sialorrhea intensity to 0—1 points on the PSIVS, compared to 2—3 points at baseline. Following the reduction in sialorrhea and subsequent rehabilitation, 51 patients improved their feeding route, transitioning from tube or gastrostomy to oral or combined feeding. Decannulation was successfully performed in 14 patients. The incidence of aspiration pneumonia was 5.2% (3 cases) in the Main group, compared to 20.7% (12 cases) in the Control group. No serious adverse events were observed. Two patients experienced mild dry mouth, which resolved within one month. Conclusion. The integration of salivary gland chemodenervation with incobotulinumtoxinA (100 U) into the diagnostic and therapeutic algorithm for neurogenic dysphagia and posterior sialorrhea represents an effective and safe strategy for preventing aspiration complications. This intervention significantly reduces sialorrhea intensity and the incidence of aspiration pneumonia, enhances swallowing function, facilitates patient care, and improves rehabilitation outcomes for patients with severe neurological disorders, beginning in the acute phase. Adoption of this method in routine rehabilitation practice is recommended to decrease mortality and disability rates and to alleviate the financial burden on the healthcare system.

项与 A型肉毒毒素 (Biotecon) 相关的新闻（医药）

2026-05-12

·BioSpace

Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes

Merz Therapeutics to present 11 abstracts at ISPRM World Congress 2026, highlighting its commitment to improving outcomes for people living with movement disorders Updated analysis indicates that optimizing botulinum toxin dosing over multiple injection cycles may be an important factor in improving outcomes in people living with limb spasticity, with available clinical data suggesting support for flexible, individualized dosing with incobotulinumtoxinA (XEOMIN ® ) Updated meta-analyses examining secondary treatment failure and neutralizing antibodies suggest a potential for sustained long-term treatment response with incobotulinumtoxinA (XEOMIN ® ) FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced it will present 11 scientific abstracts at the International Society of Physical and Rehabilitation Medicine (ISPRM) 2026 World Congress. Taking place from May 17 th to May 21 st in Vancouver, Canada, the presentations will feature key data on optimal dosing strategies, immunogenicity and the potential for sustained long-term treatment response with XEOMIN ® (incobotulinumtoxinA), underscoring the company's commitment to advancing the science behind durable clinical outcomes in neurorehabilitation. "Our presence at ISPRM underscores our deep commitment to advancing the science behind improved patient care," said Stefan König, CEO, Merz Therapeutics. "We believe that by furthering the understanding of long-term treatment efficacy, we can empower clinicians to better support people affected in achieving their functional goals. Our patient-centric research complements this by ensuring we never lose sight of the outcomes that truly matter to patients." Spasticity is a chronic condition requiring long-term management, and treatment success can be influenced by factors such as appropriate dose, injection intervals and the potential for a patient to develop an immune response that reduces efficacy. 1-3 The data presented provides clinicians with valuable insights into optimizing patient care, supporting the principle of persisting with treatment while also addressing how a low risk of immunogenicity is crucial for maintaining therapeutic response. "Treating spasticity is a long-term journey we take together with people affected by the condition,” said Dr. Stefan Albrecht, CSO, Merz Therapeutics. "Our aim is to offer a therapy option that meets people’s needs today and remains a reliable choice for years to come. This research delivers robust data on key aspects such as immunogenicity, an important factor in ensuring treatment durability and sustained effectiveness as patients’ needs evolve over time." ISPRM congress attendees can connect with Merz Therapeutics at booth 306 to learn more about the company's research and commitment to improving outcomes in people with spasticity and other movement disorders. Merz Therapeutics presentations at ISPRM 2026 Topic Abstract title Location and Time IncobotulinumtoxinA dose optimization Goal Attainment and Ambulation With Increasing Doses of IncobotulinumtoxinA: A Post Hoc Analysis of the TOWER Study Tuesday, May 19, 2026 6:00 PM - 7:30 PM 300 Section Immunogenicity and potential for long-term efficacy with IncobotulinumtoxinA A systematic review and meta-analysis of neutralizing antibodies after treatment with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA across multiple indications Secondary treatment failure with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA: a systematic review and meta-analysis IncobotulinumtoxinA in upper-limb spasticity Improvement in upper limb spasticity patterns in the elderly following treatment with incobotulinumtoxinA: a pooled analysis Tuesday, May 19, 2026 6:00 PM - 7:30 PM 300 Section Moderate-to-severe upper limb spasticity patterns in the elderly are improved following treatment with incobotulinumtoxinA: a pooled analysis Tuesday, May 19, 2026 6:00 PM - 7:30 PM 300 Section IncobotulinumtoxinA in lower-limb spasticity IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy: Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE) Paratonia management Botulinum neurotoxin type-A in the treatment of patients with paratonia Digital integration Use of a Smartphone App (iFlexo) to Support Rehabilitation in Post-Stroke Spasticity: A Proof-of-Concept Study Patient and caregiver perspectives in spasticity Measuring spasticity in clinical trials – which endpoints are most relevant to patients? Barriers and facilitators to clinical trial involvement for patients with spasticity Peripheral neuropathic pain Paving the Way for a New Local Peripheral Neuropathic Pain Treatment: Proof-of-concept Clinical Trial with IncobotulinumtoxinA (PaiNT) About Merz Therapeutics Merz Therapeutics GmbH is dedicated to delivering better outcomes for more patients. With science as its foundation and the patient experience as its focus, the company relentlessly pursues innovative treatments and partnerships to address unmet needs in movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and is active in more than 80 countries. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company with a more than 115-year legacy. With passion and purpose, Merz Therapeutics continues to advance care in specialty neurology in ways that benefit both patients and society. Please visit . References: Shtefan V, Fletcher J, Duclos OA. Causes of Botulinum Toxin Treatment Failure. Clin Cosmet Investig Dermatol . 2022;15:1045-1049. Published 2022 Jun 7. doi:10.2147/CCID.S363321. Ketchum N, Carda S, O'Dell M, Säterö P, Jacinto J, Deltombe T, Francisco G. Module 4: Optimizing Outcomes in Spasticity Treatment. The Journal of the International Society of Physical and Rehabilitation Medicine 5(Suppl 1):p S50-S60, June 2022. | DOI: 10.4103/2349-7904.347810. U.Walter, P.Albrecht, W.Carr, and H.Hefter, “Systematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications,” European Journal of Neurology 32, no. 8 (2025): e70289, . Contacts Media Contact: Merz Therapeutics GmbH Luke Anthony Mircea-Willats Global Communications & Strategic Affairs merztherapeutics@merz.com

2026-04-28

·Business Wire

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin Delivery System for Overactive Bladder

NEW YORK--(BUSINESS WIRE)--Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is designed to enable effective delivery of botulinum toxin into the bladder wall without the need for needles. The Phase 2 study is expected to enroll approximately 210 patients across sites in the United States and Europe and will evaluate the safety and efficacy of Vibe-enabled delivery of botulinum toxin type A. The Company anticipates initiating patient enrollment in [Q3 2026]. “FDA clearance of this IND is an important milestone for Vensica and validates the clinical rationale behind the ViXe program,” said Avner Geva, Chief Executive Officer of Vensica Medical. “Botulinum toxin is a proven therapy for OAB, but needle-based delivery remains a barrier for many patients. We believe ViXe has the potential to expand access to a much broader population.” “The Vibe platform was specifically engineered to overcome biological barriers that have historically limited needle-free delivery of large-molecule drugs,” said Avi Eftel, Co-Founder and Chief Technology Officer of Vensica Medical. “We look forward to executing this study and generating data to further demonstrate the clinical value of our approach.” “This IND clearance represents a key milestone in Vensica’s development and highlights the potential of the ViXe program,” said Ken Berlin, Executive Chairman of the Board of Vensica Medical. “A needle-free approach to botulinum toxin delivery could meaningfully expand patient access and create significant value for patients, partners, and investors.” The IND clearance triggers a contractual development milestone payment from Vensica’s strategic partners, supporting execution of the Phase 2 trial. Vensica is supported by its investors and strategic partners, including Merz Pharma, Laborie, and Israel Biotech Fund. About Vensica Medical Vensica Medical is a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases. The Company’s proprietary Vibe® platform uses focused ultrasound to enable localized delivery of biologic and small-molecule drugs into the bladder wall. Vensica’s lead program, ViXe, combines the Vibe system with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder. For more information, please visit [www.vensica.com].

2026-04-25

·有驾

满脸褶子有救星啦？全球首款！重庆自主研发除皱针上市！

个人观点，仅供参考家人们，好消息！咱们重庆自己造的“除皱针”拿到“准生证”了！这可是全球头一款用基因重组技术搞出来的肉毒素，跟以前从细菌里提取的老办法彻底说拜拜了。以前打一针进口的，钱包得瘪下去一大块，现在国产的来了，价格有望更亲民，而且效果据说能管6到9个月，比不少进口的还持久。这下，对付咱脸上那一道道像苞米地垄沟似的皱纹，终于有了新的“重庆武器”。不过，先别急着找地方扎针。这玩意儿再厉害，它也是正儿八经的医疗用毒性药品，跟平时打疫苗一个性质，可不是在美容院、工作室就能随便来一针的玩意儿。以前央视都曝光过，黑市上那些来路不明的“水货”、“假货”，打完脸没平，嘴先歪了的事儿可不少。所以，变美这事儿，安全永远是第一位。这款名叫“芮妥欣®”的除皱针，是重庆誉颜制药有限公司鼓捣出来的。这家公司虽然2020年才成立，但来头不小，是广州一家生物医药科技公司的产业化基地。它这次成功，可不是偶然。重庆这几年铆足了劲要发展生物医药产业，把它当成六个要搞成千亿规模的特色产业之一来抓。为了支持像誉颜这样的创新药企业，重庆市政府去年底还专门出台了25条政策，从研发到上市全链条给企业“撑腰”。在重庆，像誉颜这样搞创新药研发的企业和平台，现在有23家。除了这款除皱针，重庆造的创新药这两年确实有点“杀疯了”的感觉。就在前不久，重庆精准生物技术有限公司研发的一款治疗儿童白血病的CAR-T细胞新药“普基奥仑赛注射液”也获批了，这是国内首款、全球第二款针对这个病的药，给不少家庭带来了新希望。还有一个叫智翔金泰的公司，它的创新药“赛立奇单抗注射液”不仅实现了重庆创新药“零的突破”，治银屑病和强直性脊柱炎，最近还成功进了国家医保目录，让更多患者能用得起。更厉害的是，这家公司的另一款双抗药物，还卖出了海外授权，交易额高达7.12亿美元，创了重庆生物药出海的首单纪录。这些药能这么快从实验室走到患者身边，离不开药监部门的“神助攻”。为了帮“普基奥仑赛”早点上市，重庆市药监局组织专人提前研究超低温抽样，受理后一天内就搞定抽样送检，还搞模拟检查帮企业提前整改问题。他们优化流程，把国家核查和省级检查合并一起做，让投产周期硬是缩短了一两个月。这种“全程陪跑”式的服务，在智翔金泰的药品上市过程中也一样，药监局跑了企业十几次做指导，让药品获批比平均时间提前了100多天。重庆发展生物医药，有个核心阵地叫“重庆国际生物城”。这里被定为创新药产业的重要承载地，全市一半以上的在研创新药项目都集中在这儿。光是今年前11个月，这里就签了21个新项目，协议投资额超过100亿元。政府还建立了专门的协调机制，集合了21个市级部门的力量，帮企业解决从药品审评审批、临床试验到市场准入、融资贷款的各种难题。比如智翔金泰早期研发缺钱，政府就帮忙协调了3亿元的贷款。除了这些高大上的创新药，重庆药企在闯国际市场上也没闲着。今年1月，重庆润生药业有限公司自主研发的一款治疗哮喘的吸入粉雾剂，正式获得了美国FDA的批准。这可是首个由中国企业自主研发并获得FDA批准的吸入粉雾剂产品。为了通过FDA严苛的检查，企业把生产全过程拍成视频发给对方都不行，FDA坚持要派人来实地看。 2023年，两名检查员来了，检查细致到连记录用的笔为什么是蓝色的都要问清楚——因为蓝色笔迹复印后会变色，防止造假，这体现了对药品生产质量管理规范的严格遵守。整整五天的“显微镜式”检查后，企业以“零缺陷”的成绩通过。说回咱们最关心的打除皱针。不管打的是进口的“保妥适BOTOX”、“吉适”，还是国产的“衡力”，或者是现在新出的这款“重庆造”，第一要务永远是安全。国家有明确规定，肉毒素是毒性药品，美容院、理发店、美甲店、工作室、甚至网购平台，都严禁销售和使用。合法的注射地点，必须是取得了《医疗机构执业许可证》或者经过备案的医疗美容诊所，而且诊疗科目里得有“美容外科”或“美容皮肤科”。给你打针的人，必须是持有《医师执业证书》的医生，并且还得是完成了美容主诊医师备案的专业人士。那些自称“美容导师”、“老师”的人，是绝对没有资格给你注射的。在重庆，像陆军军医大学西南医院、新桥医院、重庆医科大学附属第一医院、第二医院等公立三甲医院的整形美容科，都是具备这些资质的正规选择。去打针前，一定要学会看药。合法的肉毒素产品，包装上一定有中文标识，明确写着适应症、厂家等信息。目前国家批准的正规产品只有几种，进口的包括保妥适（BOTOX）、吉适（Dysport）、乐提葆（Letybo）、思奥美（Xeomin），国产的主要有衡力，以及现在新加入的重庆誉颜的芮妥欣®。每个正规产品的包装盒上，都有一个20位的“中国药品电子监管码”。你当场用手机支付宝扫一扫，就能看到这瓶药的生产、流通信息，是验明正身最直接的办法。有个坑要特别注意：有些机构可能给你看真药盒，扫码也没问题，但配药时背过身去，可能就把药调包了。所以，最好要求医生或护士当面配药，别让药品离开你的视线。你甚至可以拍照记录下药瓶和监管码，或者要求他们把监管码剪下来贴在你的病历本上。价格上，也别贪小便宜。在重庆，打肉毒素除皱，根据部位不同，价格一般在几百到几千元不等。比如去眉间纹，大概在800到1800元一次；去鱼尾纹在1000到2000元；瘦脸针则在2000到4000元左右。如果遇到远低于市场价的“百元瘦脸针”，那基本可以断定是假药或者严重稀释的产品，风险极大。打完针也不是就万事大吉了。注射后如果出现头晕、吞咽困难、呼吸急促、肌肉无力这些情况，别犹豫，赶紧打120，这可能是中毒的迹象。正常的术后护理也要注意，比如短期内避免按摩注射部位、不要躺得太平以防药物扩散、注意饮食禁忌等。所以，想靠一针变年轻，心情可以理解，但脑子必须清醒。认准正规机构、正规医生、正规药品，这三样缺一不可。重庆造出了好药，给了我们多一个可靠的选择，但把好药安全、有效地用到自己脸上，还得靠我们自己睁大眼睛。

100 项与 A型肉毒毒素 (Biotecon) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	A型肉毒毒素 (Biotecon)	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
颈肌张力障碍	澳大利亚	Merz Australia Pty Ltd.	2023-11-28
鱼尾纹	澳大利亚	Merz Australia Pty Ltd.	2023-11-28
额头皱纹	澳大利亚	Merz Australia Pty Ltd.	2023-11-28
下肢痉挛	日本	Teijin Pharma Ltd.	2020-06-29
上肢痉挛	日本	Teijin Pharma Ltd.	2020-06-29
上下肢痉挛	美国	Merz Pharmaceuticals LLC	2015-12-22
眉间纹	美国	Merz Pharmaceuticals LLC	2011-07-20
眼睑痉挛	美国	Merz Pharmaceuticals LLC	2010-07-30
斜颈	美国	Merz Pharmaceuticals LLC	2010-07-30
流涎	奥地利	Merz Pharmaceuticals GmbH	2007-10-24
流涎	比利时	Merz Pharmaceuticals GmbH	2007-10-24
流涎	保加利亚	Merz Pharmaceuticals GmbH	2007-10-24
流涎	克罗地亚	Merz Pharmaceuticals GmbH	2007-10-24
流涎	塞浦路斯	Merz Pharmaceuticals GmbH	2007-10-24
流涎	捷克	Merz Pharmaceuticals GmbH	2007-10-24
流涎	丹麦	Merz Pharmaceuticals GmbH	2007-10-24
流涎	爱沙尼亚	Merz Pharmaceuticals GmbH	2007-10-24
流涎	芬兰	Merz Pharmaceuticals GmbH	2007-10-24
流涎	法国	Merz Pharmaceuticals GmbH	2007-10-24
流涎	德国	Merz Pharmaceuticals GmbH	2007-10-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性盆腔疼痛综合征	临床3期	法国	Merz Pharmaceuticals GmbH	2026-02-09
原发性痛经	临床3期	法国	Merz Pharmaceuticals GmbH	2026-02-09
颈阔肌突出	临床3期	美国	Merz Aesthetics, Inc.	2025-08-27
偏头痛	临床3期	美国	Merz Therapeutics GmbH	2025-08-21
偏头痛	临床3期	奥地利	Merz Therapeutics GmbH	2025-08-21
偏头痛	临床3期	加拿大	Merz Therapeutics GmbH	2025-08-21
偏头痛	临床3期	捷克	Merz Therapeutics GmbH	2025-08-21
偏头痛	临床3期	丹麦	Merz Therapeutics GmbH	2025-08-21
偏头痛	临床3期	法国	Merz Therapeutics GmbH	2025-08-21
偏头痛	临床3期	德国	Merz Therapeutics GmbH	2025-08-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04766723 (CTgov)	临床2期	特发性震颤	78	NT 201 (Unilateral Treatment Period: NT 201)	淵積壓繭鬱襯艱積鏇憲(積鏇選網願糧艱鏇膚範) = 觸鏇鑰艱選積齋淵餘膚觸構糧壓觸鬱襯窪襯齋 (願願壓夢鹹遞醖鹹顧衊, 0.140) 更多	-	2026-04-28
				Placebo (Unilateral Treatment Period: Placebo)	淵積壓繭鬱襯艱積鏇憲(積鏇選網願糧艱鏇膚範) = 鑰鹽淵鏇艱膚顧築範選觸構糧壓觸鬱襯窪襯齋 (願願壓夢鹹遞醖鹹顧衊, 0.180) 更多
MDS2025	N/A	流涎	35	IncobotulinumtoxinA 100 U	鏇醖願淵獵積願餘鏇淵(願憲鏇憲製糧膚鏇醖構) = Dry mouth, swallowing difficulties and taste disturbances were the only treatment-related adverse events observed. Overall in 32/213 treatment cycles (15.0 % of overall cycles) did side-effects occur. Swallowing difficulties occurred in 18 cycles (8.5%). These side-effects spontaneously resolved. In six patients (17,1%) a dose reduction to 75 U incobotulinum toxin or lower was warranted because of moderate swallowing difficulties. Treatment interruption was never warranted. 襯糧淵憲夢範願襯淵餘 (膚廠網顧窪窪顧鹽積願 )	积极	2025-10-05
NCT04965311 (CTgov)	临床2期	胰腺瘘 \| 胰腺癌	4	Botulinum Toxin Type A	鑰憲簾鏇鹽窪憲窪繭築 = 夢遞築遞淵夢淵淵積願構願壓蓋選範膚醖憲鬱 (築製壓鏇衊鬱築膚構鏇, 選淵壓簾蓋鹹顧網鑰鹽 ~ 遞糧網積選憲製顧構衊) 更多	-	2025-05-13
TOWER (MDS2024)	N/A	肌肉痉挛	70	IncobotulinumtoxinA (spasticity due to cerebral causes)	鏇鹽糧積艱範積鹹窪衊(夢夢衊觸構網窪夢繭壓) = 艱範遞餘鏇構選構壓製繭積艱糧願鑰網築鑰壓 (鹹壓網鏇願餘鏇餘選鏇 ) 更多	积极	2024-09-27
MDS2024	N/A	流涎	36	IncobotulinumtoxinA 100 U	壓憲醖鏇範艱製網廠選(蓋鏇築膚觸憲鏇鹽襯齋) = 繭襯範廠壓艱遞餘顧夢襯襯網壓鏇築選夢醖選 (襯淵鬱製選獵願壓壓醖, 1.6) 更多	积极	2024-09-27
NCT04622254 (ULTRA II, CTgov)	临床3期	-	368	Placebo (Main Period: Placebo (Group P))	獵積構夢觸廠夢壓願構 = 襯簾蓋廠淵鹹製醖壓遞淵繭蓋鹽廠蓋觸願鏇淵 (構簾鬱鹽製鬱顧夢鏇顧, 範範窪窪襯觸艱鹽簾壓 ~ 選鹽壓夢襯顧齋衊蓋觸) 更多	-	2024-08-06
				NT 201 (Main Period: NT 201 (Group U))	獵積構夢觸廠夢壓願構 = 繭淵選艱糧遞壓糧憲醖淵繭蓋鹽廠蓋觸願鏇淵 (構簾鬱鹽製鬱顧夢鏇顧, 網艱繭積簾鏇壓願壓醖 ~ 範衊簾鏇願襯窪齋願觸) 更多
NCT04594213 (ULTRA I, CTgov)	临床3期	-	362	Placebo (Main Period: Placebo (Group P))	糧糧鹹淵觸網鹽壓壓顧 = 構顧簾齋鑰願鬱鑰鑰鑰鏇製窪鏇壓糧範憲廠網 (鑰廠壓襯糧襯淵艱憲構, 糧鬱簾鏇鏇齋廠憲淵獵 ~ 糧壓範範夢選簾醖築簾) 更多	-	2024-05-08
				NT 201 (Main Period: NT 201 (Group U))	糧糧鹹淵觸網鹽壓壓顧 = 艱夢觸衊觸築鏇獵襯鹽鏇製窪鏇壓糧範憲廠網 (鑰廠壓襯糧襯淵艱憲構, 鹹簾遞製齋顧糧觸範鑰 ~ 醖糧醖願獵觸餘構壓觸) 更多
P8-3.004 (AAN2024)	N/A	颈肌张力障碍	451	IncobotulinumtoxinA	築艱鑰糧製膚願繭蓋夢(艱顧範遞憲積廠範齋觸) = 壓簾壓鹹蓋鏇網廠糧選範鹽窪蓋鹽遞壓網築觸 (夢顧繭醖網淵蓋鹹餘鑰 ) 更多	积极	2024-04-09
				Placebo	築艱鑰糧製膚願繭蓋夢(艱顧範遞憲積廠範齋觸) = 膚獵製鏇築憲網顧糧簾範鹽窪蓋鹽遞壓網築觸 (夢顧繭醖網淵蓋鹹餘鑰 ) 更多
NCT03806933 (CTgov)	临床2期	-	241	MP+NT 201 (Stage 1 and 2 Pooled: NT 201 20 U)	獵鹹觸憲襯製醖醖壓獵(顧夢鹹蓋製壓鏇鏇築糧) = 顧餘積製鏇蓋壓製夢鬱繭窪範網艱獵願憲鑰觸 (夢鏇積網鏇願艱糧夢網, 製糧鑰製獵膚餘願艱積 ~ 糧窪願顧製選憲糧構製) 更多	-	2023-10-04
				MP+NT 201 (NT 201 50 U)	獵鹹觸憲襯製醖醖壓獵(顧夢鹹蓋製壓鏇鏇築糧) = 積選廠襯觸糧糧廠襯網繭窪範網艱獵願憲鑰觸 (夢鏇積網鏇願艱糧夢網, 窪繭壓範憲膚憲觸憲艱 ~ 艱鹹夢襯製鹹衊艱壓醖) 更多
MDS2023	N/A	-	451	IncobotulinumtoxinA	壓簾壓壓遞鹹顧範範糧(製鑰醖衊鏇鹽範鬱餘選) = 簾構憲艱齋範膚夢艱積鏇鹽觸窪膚構構製餘艱 (窪顧醖蓋範膚襯積觸淵 )	-	2023-08-27
				Placebo	壓簾壓壓遞鹹顧範範糧(製鑰醖衊鏇鹽範鬱餘選) = 簾淵顧繭願襯顧繭齋鏇鏇鹽觸窪膚構構製餘艱 (窪顧醖蓋範膚襯積觸淵 )